Could a simple injection replace major surgery for ovarian cancer staging?
NCT ID NCT06963268
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a sentinel lymph node technique, where a small amount of radioactive tracer and dye is injected to find the first lymph nodes that might contain cancer. In 200 women with early-stage ovarian cancer, doctors will compare this method to the standard approach of removing many lymph nodes. The goal is to see if the less invasive technique is accurate enough to replace the more extensive surgery, which could mean fewer side effects and faster recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sentinel lymph node technique (radioactive tracer and dye injection)
- What this could lead to
- If successful, this technique could replace extensive lymph node removal, reducing surgical complications and recovery time for early-stage ovarian cancer patients.
- What could go wrong
- This is a Phase 3 trial, but the technique may not be accurate enough to replace standard surgery, and there is a risk of missing cancer spread.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitario y Politécnico La Fe
RECRUITINGValencia, Valencia, 46026, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot ovarian cancer before it starts?
- Could centralized surgery boost ovarian cancer survival?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw
- New drug duo aims to outperform chemo in ovarian cancer
- Blood test may spot ovarian cancer return months before scans